Timoptic XE®
Timolol Maleate 0.25% or 0.5% · ophthalmic gel-forming solution
Antiglaucoma
Approved uses
Elevated IOP in ocular hypertension or open-angle glaucoma
1 drop (0.25% or 0.5%) in the affected eye(s) QD
OFF-LABELNot in the FDA label for this product
Superficial infantile hemangioma, including periocular lesions
Timolol maleate 0.5% gel applied to the lesion, maximum 0.5 mg daily, for 24 weeks (trial regimen)
RCT · n=41 · gel unspecified
Double-blind RCT in 41 infants aged 5 to 24 weeks with non-ulcerated superficial lesions away from mucosal surfaces (32 completed): blinded photographic color improvement at week 24 (P=.003), a higher proportion of treated lesions reduced in size by more than 5% at weeks 20 and 24 (P<.02), and no significant difference in heart rate or blood pressure. Single small trial, and it does not identify the gel used as this product.
Contraindications
- Bronchial asthma
- A history of bronchial asthma
- Severe chronic obstructive pulmonary disease
- Sinus bradycardia
- Second or third degree atrioventricular block
- Overt cardiac failure
- Cardiogenic shock
- Hypersensitivity to any component of this product
0.25% and 0.5% gel forming solution, 5 mL in a 7.5 mL dispenser bottle
Non-selective beta-1 and beta-2 adrenergic receptor blocker that reduces elevated, as well as normal, IOP. The precise mechanism is not clearly established; studies of timolol maleate ophthalmic solution suggest its predominant action may be related to reduced aqueous formation, with a slight increase in outflow facility in some studies. The gellan gum vehicle gels on contact with the precorneal tear film and is then removed by tear flow.
Warnings & Precautions
- Systemic absorption: The same adverse reactions found with systemic beta-adrenergic blockers may occur with topical ophthalmic use. Severe respiratory and cardiac reactions, including death due to bronchospasm in patients with asthma, and rarely death in association with cardiac failure, have been reported after systemic or ophthalmic timolol maleate.
- Cardiac failure: In patients with diminished myocardial contractility, beta-adrenergic receptor blockade may precipitate more severe failure. In patients without a history of cardiac failure, continued depression of the myocardium can, in some cases, lead to cardiac failure. Discontinue at the first sign or symptom of cardiac failure.
- Obstructive pulmonary disease: Patients with chronic obstructive pulmonary disease of mild or moderate severity, bronchospastic disease, or a history of bronchospastic disease should, in general, not receive beta-blockers.
- Major surgery: Withdrawal of beta-blockers before major surgery is controversial. Blockade impairs the ability of the heart to respond to beta-adrenergically mediated reflex stimuli and may augment the risk of general anesthesia. Protracted, severe hypotension during anesthesia and difficulty in restarting and maintaining the heartbeat have been reported. Some authorities recommend gradual withdrawal before elective surgery; if necessary, effects may be reversed by sufficient doses of adrenergic agonists.
- Diabetes mellitus: Use with caution in patients subject to spontaneous hypoglycemia or in diabetic patients (especially those with labile diabetes) receiving insulin or oral hypoglycemic agents. Beta-blockers may mask the signs and symptoms of acute hypoglycemia.
- Thyrotoxicosis: Beta-blockers may mask certain clinical signs (e.g., tachycardia) of hyperthyroidism. Avoid abrupt withdrawal in patients suspected of developing thyrotoxicosis, because it might precipitate a thyroid storm.
- Anaphylaxis: Patients with atopy or prior severe anaphylaxis may be more reactive on re-challenge and unresponsive to usual epinephrine doses.
- Muscle weakness: Beta-adrenergic blockade has been reported to potentiate muscle weakness consistent with certain myasthenic symptoms (e.g., diplopia, ptosis, and generalized weakness). Timolol has been reported rarely to increase muscle weakness in some patients with myasthenia gravis or myasthenic symptoms.
- Angle-closure glaucoma: Little or no effect on the pupil, so not for use alone in angle closure.
- Choroidal detachment: Reported with aqueous suppressant therapy after filtration procedures.
- Cerebrovascular insufficiency: Use with caution because of potential effects on blood pressure and pulse; consider alternative therapy if signs or symptoms suggesting reduced cerebral blood flow develop after starting treatment.
- Bacterial keratitis: Reported with inadvertently contaminated multi-dose containers, mostly in eyes with concurrent corneal disease or a disrupted epithelial surface. Serious damage to the eye and subsequent loss of vision may result from using contaminated solutions.
- Contact lens wear: Not studied in patients wearing contact lenses.
- Additive effects of beta-blockade: Patients on an oral beta-blocker should be observed for potential additive effects, both systemic and on intraocular pressure; two topical beta-blockers together are not recommended. Potentiated systemic beta-blockade (e.g., decreased heart rate, depression) has been reported with CYP2D6 inhibitors (e.g., quinidine, SSRIs).
- Atrioventricular conduction disturbances: Use caution with oral or intravenous calcium antagonists because of possible atrioventricular conduction disturbances, left ventricular failure, or hypotension; in patients with impaired cardiac function, coadministration should be avoided. Digitalis with calcium antagonists may have additive effects in prolonging atrioventricular conduction time.
- Hypotension and marked bradycardia: Close observation is recommended with catecholamine-depleting drugs such as reserpine, because of possible additive effects and the production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.
Common Side Effects
Transient blurred vision on instillation was reported in approximately one in three patients, lasting from 30 seconds to 5 minutes, and may impair hazardous tasks such as driving; less than 1% of patients discontinued for it. Burning and stinging occurred in approximately one in eight patients, comparable to TIMOPTIC. Adverse experiences reported in 1-5% of patients were ocular pain, conjunctivitis, discharge, foreign body sensation, itching and tearing, and systemic headache, dizziness, and upper respiratory infections. Bradycardia, arrhythmia, hypotension, heart block, cardiac failure, bronchospasm (predominantly in patients with preexisting bronchospastic disease), depression, and increased signs and symptoms of myasthenia gravis have been reported with this or other timolol formulations. A slight reduction in resting heart rate was observed in some patients on the 0.5% dose.
Pregnancy: No adequate and well-controlled studies in pregnant women; use only if the potential benefit justifies the potential fetal risk (animal studies showed no malformations, with increased fetal resorptions in rabbits at 14,000 times the ophthalmic exposure without apparent maternotoxicity).
Lactation: Timolol is detected in human milk after oral and ophthalmic dosing; because of the potential for serious adverse reactions in nursing infants, decide whether to stop nursing or the drug, weighing its importance to the mother.
Safety and effectiveness of timolol maleate ophthalmic solution established in pediatric patients aged 2 years and older; not established below 2 years.